Pfizer investors stand with CEO Read even though he is 0 for 2 on megamergers

Eric Palmer

CEO Ian walked away from its $ 160 billion merger with Allergan this week after U.S. Treasury Department rule changes sucked the value out of its tax inversion benefits. But Pfizer are not walking away from , this was the second time he was unable to pull off a major merger.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS